Dicycloplatin DCP CAS: 287402-09-9

CAS NO: 287402-09-9
Dicycloplatin DCP
Chemical Name: Dicycloplatin (DCP)
Molecular Formula: C12H18N2O8Pt
Formula Weight: 513.37
CAS No.: 287402-09-9
Description Review
Description

Dicycloplatin (DCP) is a chemotherapy drug used in the treatment of various types of cancer, including lung cancer, bladder cancer, and gastric cancer. The chemical name for Dicycloplatin is cis-diamminecyclohexaneplatinum(II) chloride hydrate. It has the molecular formula C8H20Cl2N2Pt and a formula weight of 414.23 g/mol. The CAS number for Dicycloplatin is 287402-09-9.

Top ten keywords from Google and Synonyms:

  1. Dicycloplatin mechanism of action
  2. Dicycloplatin side effects
  3. Dicycloplatin dosage
  4. Platinum-based chemotherapy
  5. Non-small cell lung cancer
  6. Bladder cancer medication
  7. Gastric cancer treatment
  8. Antineoplastic drug
  9. Chemotherapy drug resistance
  10. Platinum-containing compound

Health benefits of this product: Dicycloplatin is primarily used to treat certain types of cancer, including lung cancer, bladder cancer, and gastric cancer. This medication works by interfering with the DNA inside cancer cells, which prevents them from dividing and growing. By doing so, Dicycloplatin can help slow or stop the growth of cancerous tumors and improve overall survival rates.

Potential effects: The potential effects of Dicycloplatin can vary depending on the type of cancer being treated, as well as other factors such as the individual's overall health and response to treatment. In general, this medication has been shown to be effective at slowing or stopping the growth of cancerous tumors and improving overall survival rates in patients with lung, bladder, and gastric cancer.

Product mechanism: Dicycloplatin belongs to a class of chemotherapy drugs known as platinum-based compounds. These medications work by binding to and damaging the DNA inside cancer cells, which prevents them from dividing and growing. By doing so, platinum-based compounds like Dicycloplatin can help slow or stop the growth of cancerous tumors and improve overall survival rates in patients with certain types of cancer.

Safety: Like all chemotherapy drugs, Dicycloplatin can cause side effects, some of which can be severe or life-threatening. It is important to discuss any concerns or questions with a healthcare provider before starting this medication. Additionally, patients who take Dicycloplatin may need to have regular blood tests and other monitoring to ensure that their blood counts and organ function are within normal limits.

Side effects: The most common side effects of Dicycloplatin include nausea, vomiting, diarrhea, and loss of appetite. Other potential side effects include fatigue, hair loss, peripheral neuropathy, and an increased risk of infection. Some patients may also experience more serious side effects, such as kidney damage or allergic reactions. If any side effects occur, it is important to notify a healthcare provider right away.

Dosing information: The recommended dose of Dicycloplatin varies depending on the type of cancer being treated, as well as the individual patient's age, weight, and overall health. It is important to follow the dosing instructions provided by a healthcare provider and not exceed the recommended dose. If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next dose, in which case the missed dose should be skipped.

Conclusion: Dicycloplatin is an effective chemotherapy drug used in the treatment of lung cancer, bladder cancer, and gastric cancer. This medication works by binding to and damaging the DNA inside cancer cells, which prevents them from dividing and growing. While generally considered safe, there are potential side effects associated with its use, and it is important to discuss any concerns with a healthcare provider. Overall, Dicycloplatin is an important medication for people with certain types of cancer that can help slow or stop the growth of cancerous tumors and improve overall survival rates

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code